HPV Vaccine Protects Against Infection 8 Years Out: Study
MONDAY, Aug. 18, 2014 (HealthDay News) -- A new long-term study shows that the human papillomavirus (HPV) vaccine appears to protect against the sexually transmitted virus for at least eight years.
HPV is thought to cause the majority of cervical cancers. Certain strains, such as HPV 16 and 18, are most strongly tied to these tumors. The virus is also believed to cause genital warts in both men and women and certain head and neck cancers.
Among the vaccinated preteens in the new study, none developed any of the diseases or conditions associated with HPV during the study period, the researchers reported.
"The body's response against HPV by making antibodies looks very good at eight years, and it seems like no booster doses will be necessary," said lead researcher Dr. Daron Ferris, director of the HPV epidemiology and prevention program at Georgia Regents University in Atlanta.
"There are all indications that the vaccine is safe, and it looks like it's effective in preventing genital warts and other diseases caused by HPV," he added.
The report was published online Aug. 18 in the journal Pediatrics.
Dr. Adriana Cadilla, a pediatrician at Miami Children's Hospital, said, "It is very promising that we now know that we are going to have protection for at least eight years."
For the study, the researchers randomly assigned 1,781 sexually inactive boys and girls aged 9 to 15 to the HPV vaccine or placebo shots. After eight years, those who received the vaccine still had antibodies against HPV, they found.
"If you haven't had your child vaccinated, please get them vaccinated," Ferris said. "It's more dangerous not to give the vaccine to your children. Thousands of people will continue to die each year if they are not vaccinated."
Despite the vaccine's benefits, only about 57 percent of girls aged 11 to 15 are getting the first dose of the vaccine, and only 33 percent are getting all three doses. Among boys, about 34 percent are getting the first dose of the vaccine, but only about 14 percent are getting all three doses, according to the U.S. Centers for Disease control and Prevention.
The CDC recommends that all kids aged 11 to 12 should get the three doses of HPV vaccine.
Ferris noted that getting all three doses is important. "The third dose is the booster dose, and that's what's going to convey long-term protection," he explained.
A survey published in the same journal issue examined the reasons more girls aren't getting vaccinated.
"Almost everybody [parents and doctors] we talked to thought getting the vaccine was a good idea," said survey author Dr. Rebecca Perkins, an assistant professor of obstetrics and gynecology at Boston University School of Medicine.
"They thought that preventing cancer is good and that all girls should get vaccinated," she said. "What was happening was a problem with timing."
Doctors weren't suggesting the vaccine for girls aged 11 to 12, Perkins said. They thought the vaccine should be given later, when girls are more likely to be sexually active, she said.
Doctors and parents were thinking more about how the virus is transmitted, rather than about the vaccine as a way to prevent cancer, she said.
"Everyone needs to focus on why we are giving the vaccine, which is to prevent HPV-associated cancers, rather than on how one gets HPV," Perkins said.
High vaccination rates were achieved when doctors looked at the HPV vaccine as a normal part of the vaccination schedule. In addition, talking about preventing cancer was a more successful approach than talking about HPV as a sexually transmitted infection, the researchers added.
Cadilla wasn't surprised by the survey findings. "We have known that we have not been doing a good job vaccinating girls and boys," she said.
Cultural prejudices about sex need to be overcome, Cadilla added. "A lot of times because HPV is a sexual disease, it will scare parents off," she said. "But you never know when your child is going to start having sex."
Cadilla advises parents to have their kids vaccinated. "You are preventing something from happening in the future," she said.
Perkins' findings were based on interviews about HPV and the vaccine with 124 parents and 37 doctors.
Visit the U.S. Centers for Disease Control and Prevention for more on the HPV vaccine.
SOURCES: Daron Ferris, M.D., director, HPV epidemiology and prevention program, Georgia Regents University, Atlanta, Ga.; Rebecca Perkins, M.D., assistant professor, obstetrics and gynecology, Boston University School of Medicine, Boston, Mass.; Adriana Cadilla, M.D., pediatrician, Miami Children's Hospital, Miami, Fla.; September 2014 Pediatrics